6 Stocks To Watch Amid Monkeypox Outbreak
6 Stocks To Watch Amid Monkeypox Outbreak
A Monkeypox outbreak has been reported in several European countries, two cases in Canada and one confirmed case in a man from Massachusetts.
據報道，幾個歐洲國家爆發了猴痘疫情，加拿大有兩例病例，馬薩諸塞州一名男子確診病例。
What's going on? Monkeypox, a relative to smallpox, is a rare disease thought to be limited to two regions in Africa and has two main types: the Central African strain, which has a fatality rate of up to 10%, and the West African strain, which has a fatality rate of around 1%. The cases in question are believed to be the less fatal West African strain.
到底怎麼回事？猴痘是一種罕見的疾病，被認為僅限於非洲的兩個地區，主要有兩種類型：中非病毒株，死亡率高達10%；西非病毒株，死亡率約為1%。有問題的病例被認為是不太致命的西非病毒株。
Fever, rash and swollen lymph nodes are among the symptoms of monkeypox. While each symptom should be taken seriously, swollen lymph nodes especially can lead to various medical concerns. It is believed that the smallpox vaccine, which was first introduced in 1796, is effective against monkeypox.
猴痘的症狀包括髮燒、皮疹和淋巴結腫大。雖然每種症狀都應該認真對待，但淋巴結腫大尤其會導致各種醫療問題。人們認為，1796年首次引入的天花疫苗對猴痘有效。
Several stocks related to vaccines and pharmaceuticals moved on the news of the outbreak; here is a list of six.
疫情爆發的消息傳出後，與疫苗和藥品相關的幾隻股票出現了波動；以下是六隻股票的名單。
Bavarian Nordic A/S - ADR (OTC:BVRNY)
Market cap: $810.95 million
巴伐利亞北歐A/S-ADR(場外交易：BVRNY)
市值：8.1095億美元
Bavarian Nordic says it is highly specialized in researching, developing and manufacturing vaccines based on viral vectors to deliver antigens targeting infectious diseases and cancers.
巴伐利亞北歐公司表示，該公司高度專業地研究、開發和製造基於病毒載體的疫苗，以運送針對傳染病和癌症的抗原。
More than that, Bavarian has built its foundation around poxviral-based vaccine platform technologies, particularly its proprietary technology, Modified Vaccinia Ankara – Bavarian Nordic (MVA-BN).
不僅如此，巴伐利亞還建立了圍繞基於痘病毒的疫苗平臺技術的基礎，特別是其專有技術，改良安卡拉-巴伐利亞北歐疫苗(MVA-BN).
MVA-BN is approved as a smallpox vaccine in the U.S., Canada and the EU.
MVA-BN在美國、加拿大和歐盟被批准作為天花疫苗。
SIGA Technologies, Inc. (NASDAQ:SIGA)
Market cap: $805.89 million
SIGA技術公司(納斯達克：SIGA)
市值：8.0589億美元
Siga Tech is a pharmaceutical company based in New York City that focuses on anti-viral smallpox treatment solutions.
SIGA Tech是一家總部位於紐約市的製藥公司，專注於抗病毒天花治療解決方案。
The company's leading product, Tecovirimat (Tpoxx), is an antiviral medication with activity against orthopoxviruses such as smallpox and monkeypox.
該公司的主導產品，Tecovirimat(Tpoxx)是一種抗病毒藥物，具有對抗天花和猴痘等正痘病毒的活性。
Siga was awarded a contract by the U.S Department of Defense on May 12 to produce approximately $7.5 million worth of the oral version of Tpoxx.
5月12日，SIGA獲得了美國國防部的一份合同，生產價值約750萬美元的口服版Tpoxx。
Chimerix Inc (NASDAQ:CMRX)
Market cap: $205 million
Chimerix Inc.(納斯達克：CMRX)
市值：2.05億美元
Chimerix is a biopharmaceutical company that develops oral antiviral treatments, including Tembexa, a smallpox oral antiviral tablet approved by the FDA in 2021.
Chimerix是一家生物製藥公司，開發口服抗病毒療法，包括Tembexa，一種天花口服抗病毒片，FDA於2021年批准。
Emergent BioSolutions (see below) announced a deal with Chimerix on Monday to acquire exclusive rights to Tembexa.
Emerent BioSolutions(見下文)週一宣佈與Chimerix達成協議，獲得Tembexa的獨家經營權。
Emergent Biosolutions Inc (NASDAQ:EBS)
Market cap: $1.76 billion
新興生物解決方案公司(納斯達克：ebs)
市值：17.6億美元
Emergent is a multinational biopharmaceutical company that develops vaccines and antibody therapeutics for infectious diseases.
Emerent是一家跨國生物製藥公司，開發傳染病疫苗和抗體療法。
The company currently produces ACAM2000, a vaccine for smallpox and announced a deal to acquire Chimerix's FDA-approved antiviral smallpox therapy.
該公司目前生產ACAM2000，一種天花疫苗，並宣佈了一項收購Chimerix的FDA批准的抗病毒天花療法的交易。
Inovio Pharmaceuticals Inc (NASDAQ:INO)
Market cap: $421.44 million
Inovio製藥公司(納斯達克：INO)
市值：4.2144億美元
Inovio is a biotech company focused on discovering, developing and commercializing synthetic DNA products for treating cancers and infectious diseases.
Inovio是一家生物技術公司，專注於發現、開發和商業化用於治療癌症和傳染病的合成DNA產品。
In 2010, Inovio made news when it announced its smallpox DNA vaccine offered 100% protection in non-human primates against a highly pathogenic monkeypox challenge after vaccination.
2010年，Inovio宣佈其天花DNA疫苗在接種後對非人類靈長類動物提供100%保護，使其免受高致病性猴痘的挑戰，這一消息引起了轟動。
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)
Market cap: $47 million
東尼克斯製藥控股公司(納斯達克：TnXP)
市值：4700萬美元
Tonix is a pharmaceutical company based in New Jersey that focuses on repurposed drugs for central nervous system conditions.
Tonix是一家總部位於新澤西州的製藥公司，專注於治療中樞神經系統疾病的改變用途的藥物。
Tonix is a producer of the TNX-801 vaccine, effective against smallpox and monkeypox.
Tonix是TheTNX-801疫苗，對天花和猴痘有效。
譯文內容由第三人軟體翻譯。